Acinetobacter pittii is a nosocomial pathogen rarely involved in community-acquired infections. We report for the first time that A. pittii can be responsible for cavitary community-acquired pneumonia and study its virulence, and discuss its pathogenesis and treatment options.
Case presentation
A 45-year-old woman with a history of smoking and systemic lupus was admitted to Nimes University Hospital (France) with coughing and sputum lasting for three weeks. Thoracic CT scanner showed cavitary pneumonia. Broncho-alveolar lavage cultures found community-acquired Acinetobacter calcoaceticus-baumannii complex. The clinical outcome was favourable after twenty-one days of antimicrobial treatment by piperacillin/tazobactam and amikacin then cefepime. Multilocus sequence typing (MLST) analyses identified an A. pittii ST249. Despite the atypical clinical presentation with an unexpected partial destruction of lung parenchyma, we found very low virulence potential of the A. pittii strain with nematode killing assays and biofilm formation test. The median time required to kill 50% of the nematodes was 7 ± 0.3 days for A. pittii ST249, 7 ± 0.2 days for A. baumanii NAB ST2 and 8 ± 0.2 days for E. coli OP50, (p > 0,05). A. pittii ST249 showed significantly slower biofilm formation than A. baumanii NAB ST2: BFI = 8.83 ± 0.59 vs 3.93 ± 0.27 at 2 h (p < 0.0001), BFI = 6.3 ± 0.17 vs 1.87 ± 0.12 at 3 h (p < 0.0001) and BFI = 3.67 ± 0.41 vs 1.7 ± 0.06 after 4 h of incubation (p < 0.01).
Conclusions
Community-acquired A. pittii should be considered as possible cause of sub-acute cavitary pneumonia particularly in a smoking and/or immunocompromised patient despite its low virulence potential.
Abkürzungen
BAL
Broncho-alveolar lavage
BFI
BioFilm Indice
CFU
Colony Forming Unit
CT-scan
Computed tomography
EUCAST
European Committee on Antimicrobial Susceptibility Testing
LT50
Median time required to kill 50% of the Fer-15 C. elegans population
MALDI-TOF
Matrix Assisted Laser Desorption Ionisation/Time Of Flight
MLST
MultiLocus Sequence Typing
NAB ST2
A. baumannii strain belonging to international clone II/ST2
OP50
Non-pathogenic E. coli
Background
The classic underlying causes of lung abscess or cavitary lung lesions are anaerobes, Streptococcus pneumonia, Streptococcus milleri group, Staphylococcus aureus and Klebsiella pneumoniae. More rarely Pseudomonas aeruginosa and other aerobic Gram-negative bacilli, Nocardia spp., Aspergillus spp. and Cryptococcus spp. could be identified [1]. To our knowledge, Acinetobacter pittii, formerly known as Acinetobacter genomospecies 3, has not been described as a cause of cavitary pneumonia before and it appears to be an unusual cause of community-acquired infections [1‐3]. However, it is increasingly described as a cause of hospital-acquired infection particularly in intensive care unit setting [4]. Here, we report the first case of cavitary community-acquired pneumonia due to A. pittii in a patient with a systemic lupus and study the virulence profile of A. pittii.
Case presentation
A 45-year-old woman, was admitted to Nimes University Hospital (France) for a cough and sputum lasting for three weeks with an unfavourable outcome despite prescription of antibiotics (cefixime then pristinamycin). She had a medical history of smoking and systemic lupus diagnosed in 1991 with moderately reduced glomerular filtration rate (57 ml/min/1.73m2), stroke and right nephrectomy in 2011. Her usual treatment included hydroxychloroquine, clopidogrel and atorvastatine.
Anzeige
At admission, she presented dyspnoea, crackles of the right lung field and normal temperature. The white blood cell count was 19 × 103 cells/μL and C reactive protein was high at 144 mg/L. Chest X-ray showed a large pulmonary cavity of the right lower lobe (Fig. 1) and computed tomography (CT-scan) showed four large cavities and nodules of the right lower lobe (Figs. 2 and 3). Blood cultures remained negative. A fibroscopy with broncho-alveolar lavage (BAL) showed local inflammation with sputum. Piperacillin/tazobactam plus amikacin was administered as empirical treatment. The BAL culture was positive with more than 104 CFU/mL of Gram negative bacilli.
×
×
×
MALDI-TOF (Matrix Assisted Laser Desorption Ionisation/Time Of Flight) analysis (Vitek MS, bioMérieux) identified A. calcoaceticus-baumannii complex (99%). Antimicrobial susceptibility was tested by disc diffusion in accordance with EUCAST (European Committee on Antimicrobial Susceptibility Testing) recommendations (version 5.0, 2015; http://www.eucast.org). The isolate was susceptible to ticarcillin, piperacillin, third and fourth generation cephalosporins, imipenem, ciprofloxacin and amikacin. Cultures for mycobacteria, Nocardia spp., Aspergillus spp. and Cryptococcus spp. were negative. Bronchial biopsy was normal.
Cavitary community-acquired pneumonia due to A. calcoaceticus-baumannii complex was considered. The antimicrobial treatment was changed to cefepime after seven days of piperacillin/tazobactam and two days amikacin. After twelve days of antimicrobial treatment (including five days cefepime) the CT-scan showed persistent excavated lung lesions. Size of the largest cavity was slightly reduced and the walls were thinner. The clinical outcome was favourable after twenty-one days of antimicrobial treatment (including fourteen days cefepime). The Positon Emission Tomography - Computed Tomography performed at the end of the antimicrobial therapy did not find hypermetabolic fixation. Six months later, CT-scan showed residual excavated lung lesions of the right lower lobe. The bronchoscopy with biopsies was normal and the BAL cultures were negative.
Species identification
As species included in A. calcoaceticus-baumannii complex are closely related, rpoB sequencing and multilocus sequence typing (MLST) (bigsdb.web.pasteur.fr) [5] were performed to characterize the taxonomic status of the strain and the clone involved in this case. The isolate was identified as A. pittii belonging to ST249.
Anzeige
Virulence study
To evaluate the virulence of the A. pittii strain, we conducted a Caenorhabditis elegans nematode killing assay, a virulence model well described to study Acinetobacter spp. virulence [6]. The median time required to kill 50% of the Fer-15 C. elegans population (LT50) was compared between A. pittii isolate and an A. baumannii strain belonging to international clone II/ST2 isolated in our laboratory (NAB ST2). In vivo kinetics of killing of C. elegans infected by A. pittii and NAB ST2 were compared with the survival curve for worms fed on non-pathogenic E. coli (OP50) using a log-rank (Mantel-cox) test.
There was no significant difference between kinetics of killing of C. elegans infected by A. pittii ST249 and NAB ST2 compared with those fed on non-pathogenic E. coli OP50, showing a very low virulence potential for the two strains equivalent to the standard feeding strain E. coli OP50 for nematodes (Fig. 4). The LT50 were 7 ± 0.3 days, 7 ± 0.2 days and 8 ± 0.2 days respectively for A. pittii ST249, NAB ST2 and E. coli OP50, (p > 0,05).
×
Given that biofilm formation is reported to favour bacterial colonization and persistence, biofilm-forming ability was investigated and kinetics of A. pittii ST249 and NAB ST2 were compared. The kinetics of the early phase of biofilm formation for A. pittii and NAB ST2 were studied using the BioFilm Ring Test® (BioFilm Control, Saint Beauzire, France) [7]. A high BioFilm Index (BFI) value (>8) corresponds to high mobility of free beads under magnetic attraction (no biofilm), while a low value (≤2) corresponds to complete immobilisation of beads (strong biofilm) [8]. BFI values between 2 and 8 indicate that biofilm formation is in progress. Three experiments with two repeats were performed per strain and per incubation time. Mean BFI were compared between each strain after 1, 2, 3, 4 and 5 h, using two-way Anova test followed by Bonferroni’s multiple comparisons test. Statistics and graphs were prepared using the software package GraphPad Prism 6.0®.
There were no significant differences between the two strains at the very beginning of kinetics (BFI = 9.27 ± 0.27 for A. pittii and 8.63 ± 0.37 for NAB ST2 at 1 h of incubation, p > 0,05) (Fig. 5). However, at the next time points, A. pittii ST249 showed a significantly slower biofilm formation than NAB ST2: BFI = 8.83 ± 0.59 vs 3.93 ± 0.27 respectively at 2 h (p < 0.0001), BFI = 6.3 ± 0.17 vs 1.87 ± 0.12 at 3 h (p < 0.0001) and BFI = 3.67 ± 0.41 vs 1.7 ± 0.06 after 4 h incubation (p < 0.01). A. pittii biofilm was constituted after 5 h of incubation (BFI = 1.77 ± 0.09).
×
Discussion and conclusions
We report the first case of cavitary community-acquired pneumonia due to an A. pittii strain with low virulence potential, in a smoking patient with systemic lupus.
A. pittii is a member of the A. calcoaceticus-baumannii complex which also includes A. baumannii, A. calcoaceticus and A. nosocomialis. As a result of advances in molecular biology, A. pittii is increasingly recognized as a significant cause of nosocomial infection, particularly in intensive care unit setting, but nevertheless remains uncommon [3]. This bacterium is rarely observed to cause community-acquired infections notably cavitary pulmonary disease [1]. A. pittii ST249 has been described only twice, in two patients with hospital-acquired infection in Germany, a country where the prevalence of A. pittii seems high among species of A. calcoaceticus-baumannii complex [9]. The proportion of A. pittii community-acquired infections is not defined because of technological limitations in species identification across laboratories worldwide [5, 10]. Prevalence may also be under-evaluated in healthy individuals because the low virulence profile does not result in clinical disease.
The large destruction of lung parenchyma with both cavitary lung lesions and pulmonary nodules in this case suggests that A. pittii is highly virulent. However, the C. elegans killing assays and the BioFilm Ring Test® showed very low virulence potential and a poor ability to form biofilm as recently observed [11, 12]. The significant variability of virulence described among A. baumannii complex species probably explains the sub-acute clinical course unlike the fulminant evolution usually associated with Acinetobacter community-acquired pneumonia in tropical areas [12‐14]. Moreover, the mortality rate for patients infected with A. pittii seems to be lower than for A. baumannii (15% versus 40%) [4, 10]. Finally, the hosts’ immune status and tobacco consumption seem to play a crucial role to facilitate infection. A. pittii and A. baumannii appear genetically and metabolically similar [15] and probably share the same risk factors for causing community-acquired infections: smoking, excessive alcohol consumption, diabetes mellitus and chronic lung disease [13, 14]. In this case, the patient is diabetic, smokes and also has lupus, a condition known to increase the risk of infection with or without immunosuppressive drugs [16]. A. pittii is widely distributed in the environment and may contaminate food and animals, thus humans could acquire skin and/or oral carriage which subsequently favours infection [13, 17]. A study with more patients would allow us to better characterize the virulence of A. pittii and the host-pathogenic interaction but seems difficult due to the low prevalence of this type of infection.
With regard to drug choice, on the one hand, initial empiric antimicrobial therapy may be inappropriate if following standard practice guidelines for community acquired pneumonia, except if a fluoroquinolone is chosen [18]. On the other hand, second line treatment is ultimately most often appropriate because A. pittii is relatively susceptible to antibiotics used in this case [4, 6]. The most effective drugs are carbapenems [5, 10]. Piperacillin/tazobactam, ticarcillin/clavulanate, ceftazidime or fluoroquinolone are alternative choices [10, 19]. However, carbapenem resistance does occur frequently in the A. calcoaceticus-baumannii complex [5] and A. pittii ST249 has been described in association with the production of a carbapenemase GIM-1 [9]. In these cases, amikacin or colistin often remain the only therapeutic option.
Anzeige
In conclusion, one case of A. pittii community-acquired pneumonia revealed by cavitary lung lesions with a sub-acute clinical course lead to describing its low virulence profile. In the setting of immunocompromised patients and tobacco consumption, evaluation of A. pittii as a possible cause of community-acquired pneumonia should be considered, particularly in case of unsatisfactory response to first line antimicrobial therapy. The clinical course seems to be less severe than when caused by A. baumannii. As we can now more easily identify A. pittii in the A. calcoaceticus-baumannii complex, studying more patients could be interesting to asses the clinical features of this type of pneumonia.
Acknowledgements
Dr. Julie Carr, for reviewing this manuscript.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Availability of data and materials
The datasets generated and analysed during the current study are not publicly available, but are stored in the medical record in Clinicom® software, in the Nimes University Hospital and are available from the corresponding author on reasonable request. Clinical data are reported according the CARE guidelines (http://www.care-statement.org/).
Anzeige
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written consent for potentially identifying information being published as a case report was obtained from patient during admission. Consent was also reconfirmed verbally prior to submission of written article for publication.
Competing interests
None of the authors has any conflict of interest to declare that could influence this work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.